Synthetic Biologics to Present at the Fifth Annual LD MICRO
Conference in Los Angeles
ROCKVILLE, Md., Nov. 30,
2012 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT:
SYN), a developer of synthetic biologics and innovative medicines
for serious infections and diseases, announced today that
Jeffrey Riley, CEO, will present at
the Fifth Annual LD MICRO Conference on Thursday, December 6, 2012 at 9:00 a.m. (PT). The conference will be held
December 5-6, 2012 at the Luxe Sunset
Bel Air Hotel in Los Angeles,
California. Synthetic Biologics' management will be
available during the conference for one-on-one meetings. Please
contact LD MICRO to schedule a meeting.
A live webcast of Synthetic Biologics' presentation can be
accessed by logging onto the internet at
http://wsw.com/webcast/ldmicro3/syn/. After the presentation, a
replay will be archived and accessible for 30 days at the same
website.
About Synthetic Biologics, Inc.
Synthetic Biologics is a biotechnology company focused on the
development of product candidates for serious infections and
diseases. Synthetic Biologics is developing a biologic for the
prevention of C. diff infection, and a series of monoclonal
antibodies (mAbs) for the treatment of serious infectious diseases,
including Acinetobacter. The Company is also developing a
synthetic DNA-based therapy for the treatment of pulmonary arterial
hypertension (PAH). In addition, the Company is developing a drug
candidate for the treatment of relapsing-remitting multiple
sclerosis (MS) and cognitive dysfunction in MS, and designing a
clinical development pathway for the treatment of amyotrophic
lateral sclerosis (ALS). For more information, please visit
Synthetic Biologics' website at www.syntheticbiologics.com.
SOURCE Synthetic Biologics, Inc.